This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
This product will be manufactured at Lupin's Pithampur facility in India
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)